<DOC>
	<DOC>NCT02402452</DOC>
	<brief_summary>This study will evaluate the pharmacokinetics, safety, and tolerability of GS-9857 in adults with severe renal impairment and matched healthy control adults.</brief_summary>
	<brief_title>Pharmacokinetics of GS-9857 in Adults With Normal Renal Function and Severe Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>All individuals: Screening laboratory values within defined thresholds for group Use of two effective contraception methods if female of childbearing potential or sexually active male For individuals with severe renal impairment: Stable chronic kidney disease Creatinine clearance (CLcr) &lt; 30 mL/min All individuals: Pregnant or nursing female or male with pregnant female partner Hepatitis B virus, hepatitis C virus (HCV) or HIV infection History of clinically significant illness or any other medical disorder that may interfere with the individual's treatment, assessment or compliance with the protocol For individuals with severe renal impairment: Anticipated to require dialysis within 90 days of study dosing</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>